Replimune Group Stock News

Replimune (REPL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

WOBURN, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolyt

Replimune Group, Inc. (REPL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnin

Replimune Group, Inc. (REPL) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed

Replimune Group, Inc. (REPL) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

WOBURN, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic im

Today, we revisit an intriguing oncology developmental company called Replimune Group, Inc. for the first time in more than a year. This week the company added drug giant Roche as a developmental part

WOBURN, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic im

Shares have lost half of their value since my March 2021 update. Currently, in ROTY we own 8% portfolio weighting with 20% gain. Key pivotal readouts are coming up year end (anti PD-1 failed melanoma)

WOBURN, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic im

Following a stronger-than-expected jobs report for June, U.S. market indexes rose on Friday as investors anticipate the Federal Reserve will continue with its aggressive interest rate hikes as it atte

Presentations include recently updated results from the skin cancer cohort of IGNYTE, an ongoing Phase 1/2 study of RP1 combined with Opdivo® (nivolumab), and trial-in-progress updates across the RP1

WOBURN, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune, will present in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference being held virtually on Friday, February 18, 2022 at 8:40 AM ET.

WOBURN, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic im

Replimune Group Inc (REPL) shares closed 1.3% lower than its previous 52 week low, giving the company a market cap of $1B. The stock is currently down 12.6% year-to-date, down 44.3% over the past 12 months, and up 56.2% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 rose 0.6%. Trading Activity Trading volume this week was 12.5% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.5. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 2233.3% The company's stock price performance over the past 12 months lags the peer average by 177.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.